inclusion criteria: 1. participants who provide written informed consent before the trial, and fully understand the trial content, process and possible adverse reactions. 2. participants who are willing and able to comply with the protocol for treatment plan, virological testing, laboratory testing and other study procedures. 3. male or female participants aged 18-75 (including 18 and 75 years old). 4. confirmed sars-cov-2 infection 120 hours prior to randomization. 5. initial onset of covid-19 symptoms/signs within 48 hours before randomization. 6. fertile participants must agree to take effective contraceptive measures.

inclusion criteria: 1. participants who provide written informed consent before the trial, and fully understand the trial content, process and possible adverse reactions. 2. participants who are willing and able to comply with the protocol for treatment plan, virological testing, laboratory testing and other study procedures. 3. male or female participants aged 18-75 (including 18 and 75 years old). 4. confirmed sars-cov-2 infection 120 hours prior to randomization. 5. initial onset of covid-19 symptoms/signs within 48 hours before randomization. 6. fertile participants must agree to take effective contraceptive measures.

inclusion criteria: participants who provide written informed consent before the trial, and fully understand the trial content, process and possible adverse reactions. participants who are willing and able to comply with the protocol for treatment plan, virological testing, laboratory testing and other study procedures. male or female participants aged 18-75 (including 18 and 75 years old). confirmed sars-cov-2 infection 120 hours prior to randomization. initial onset of covid-19 symptoms/signs within 48 hours before randomization. fertile participants must agree to take effective contraceptive measures.

inclusion criteria: participants who provide written informed consent before the trial, and fully understand the trial content, process and possible adverse reactions. participants who are willing and able to comply with the protocol for treatment plan, virological testing, laboratory testing and other study procedures. male or female participants aged 18-75 (including 18 and 75 years old). confirmed sars-cov-2 infection 120 hours prior to randomization. initial onset of covid-19 symptoms/signs within 48 hours before randomization. fertile participants must agree to take effective contraceptive measures.